In comparison with vehicle-treated APS controls, 5 mg/kg crassolide treatment significantly reduced the expression of CD80 (Figure 8a) and CD86 (Figure 8b) in CD11c+DCs (Supplemental Figure S2 and Figure 8a,b). The gene discussed is CD86; the disease is autoimmune polyendocrinopathy.